^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
cobas® KRAS Mutation Test

Company:
Roche
Type:
FDA Approved
Related tests:
over1year
KRAS Mutation in Pediatric Intracranial Germ Cell Tumors. (PubMed, Asian Pac J Cancer Prev)
Our study revealed the treatment outcomes of IGCTs in Thai children. The metastatic germinoma patient with KRAS codon 61 mutation had a poor outcome, supporting that Q61L has a clinical correlation with IGCTs.
Retrospective data • Journal
|
KRAS (KRAS proto-oncogene GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KRAS mutation • KRAS Q61L
|
cobas® KRAS Mutation Test
over1year
Clinicopathological and histomorphological association in K-ras mutated colorectal cancer (ECP 2022)
According to the certain limitations of this retro-spective study using a single detection kit that include common codon changes in K-ras gene it is obvious that further studies on the histological results and their prognostic value of rare KRAS codon variants are necessary. From the other perspective, the pre-sent study demonstrated a moderate association between KRAS-mutated CRCs and specific histology, and, to a certain degree, an association between histology and prognosis, according to KRAS mutation status.
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • RAS mutation
|
cobas® KRAS Mutation Test
over1year
Efficacy of current immunotherapies in patients (pt) with metastatic non-small cell lung cancer (NSCLC) harboring KRAS mutations (ESMO 2022)
Although KRAS G12C mut tumors exhibited higher PDL1 expression, no differences were observed in mPFS nor mOS compared to KRAS nonG12C in our cohort. Starting 1 st line IT improved mPFS, regardless of KRAS mut type, with no impact on OS.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
|
VENTANA PD-L1 (SP263) Assay • cobas® KRAS Mutation Test
2years
The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C (ELCC 2022)
A deeper understanding of biology in KRAS mutant tumors in the era of molecular testing and precision medicine is essential. Legal entity responsible for the study The authors.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
VENTANA PD-L1 (SP263) Assay • cobas® KRAS Mutation Test
over2years
Development and extensive analytical validation of deep amplicon sequencing for detecting KRAS and NRAS mutations in metastatic colorectal cancer samples. (PubMed, Neoplasma)
"RAS mutation frequencies in the Czech CRC patients were similar to previous reports, although rare mutations were also detected. DAS with short amplicons is a good strategy for routine assessment of somatic mutations in low-quality FFPE-derived DNA."
Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • NRAS mutation • RAS wild-type
|
therascreen® EGFR RGQ PCR Kit • therascreen® KRAS RGQ PCR Kit • cobas® KRAS Mutation Test
4years
Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. (PubMed, Virchows Arch)
"Anti-PD-1 therapy (pembrolizumab) prolonged overall survival compared to any other treatment...Immune checkpoint inhibitors could represent an alternative therapeutic option particularly for KRAS-mutated NSCLC patients. Further investigation into this notion is warranted in order to validate this observation."
Journal • Clinical data
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • KRAS mutation • EGFR mutation • PD-L1 overexpression • BRAF mutation • ALK rearrangement • PD-L1 negative
|
cobas® KRAS Mutation Test
|
Keytruda (pembrolizumab)